Biospectator Kim Seong-min, reporter
Construction of 5 and 6 factories and plans to advance into CDMO for cell and gene therapy revealed
Samsung Biologics’ plans to build 5 and 6 factories and to enter new cell and gene therapy (CDMO) are taking shape.
Samsung Group announced on the 24th that it will make a large-scale investment of 240 trillion won over the next three years, revealing its vision to achieve ‘the second semiconductor myth through strengthening CDMO and biosimilars’ in relation to the bio business.
This is a detailed description at the Samsung Group level after John Rim, CEO of Samsung Biologics, announced at JPM 2021 earlier this year that it would expand into new businesses in the fields of cell and gene therapy, vaccines and viral vectors.
Samsung said, “Samsung Biologics and Samsung Bioepis will continue to invest aggressively in the future and secure their role as a global biopharmaceutical production hub by constructing factories 5 and 6 in the CDMO field.” We plan to enter the CDMO market for next-generation therapeutics such as gene therapy.”
He added, “After the COVID-19 pandemic, the bio industry is changing from a ‘high value-added knowledge industry’ to a ‘national security industry’.”
Samsung has completed three CDMO plants in nine years since starting the bio business, and when the fourth plant currently under construction is completed in 2023, Samsung Biologics will secure a production capacity of 620,000 liters (CPAP).
Samsung Bioepis explained that its 10th product has now entered clinical trials and has continued to strengthen its global competitiveness, with five products being launched in the global market. Accordingly, biosimilars also plan to invest heavily in expanding and upgrading the pipeline.
In addition, Samsung aims to contribute to the vitalization of the domestic bio-industry ecosystem/cluster through ▲professional manpower ▲localization of raw and subsidiary materials ▲support for small and medium-sized biotech technologies.
.
